CLS2702C/CLS2702D

COMBINATION_PRODUCT2 trials

Sponsors

CellSeed Inc.

Conditions

Superficial Esophageal Cancer

Phase 3

Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer

CompletedNCT02866019

CellSeed Inc.Superficial Esophageal Cancer

Start: 2016-04-30End: 2019-02-28Updated: 2019-03-07

A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

TerminatedNCT04689594

CellSeed Inc.Superficial Esophageal Cancer

Start: 2021-02-04End: 2023-12-20Updated: 2026-03-27